Literature DB >> 24114146

Association between hospital case volume and the use of bronchoscopy and esophagoscopy during head and neck cancer diagnostic evaluation.

Gordon H Sun1, Oluseyi Aliu, Nicholas M Moloci, Joshua K Mondschein, James F Burke, Rodney A Hayward.   

Abstract

BACKGROUND: There are no clinical guidelines on best practices for the use of bronchoscopy and esophagoscopy in diagnosing head and neck cancer. This retrospective cohort study examined variation in the use of bronchoscopy and esophagoscopy across hospitals in Michigan.
METHODS: A total of 17,828 patients were identified with head and neck cancer in the 2006 to 2010 Michigan State Ambulatory Surgery Databases. A hierarchical, mixed-effect logistic regression was used to examine whether a hospital's risk-adjusted rate of concurrent bronchoscopy or esophagoscopy was associated with its case volume (< 100, 100-999, or ≥ 1000 cases per hospital) for those undergoing diagnostic laryngoscopy.
RESULTS: Of 9218 patients undergoing diagnostic laryngoscopy, 1191 (12.9%) received concurrent bronchoscopy and 1675 (18.2%) underwent concurrent esophagoscopy. The median hospital rate of bronchoscopy was 2.7% (range, 0%-61.1%), and low-volume (odds ratio [OR] = 27.1; 95% confidence interval [CI] = 1.9, 390.7) and medium-volume (OR = 28.1; 95% CI = 2.0, 399.0) hospitals were more likely to perform concurrent bronchoscopy compared to high-volume hospitals. The median hospital rate of esophagoscopy was 5.1% (range, 0%-47.1%), and low-volume (OR = 9.8; 95% CI = 1.5, 63.7) and medium-volume (OR = 8.5; 95% CI = 1.3, 55.0) hospitals were significantly more likely to perform concurrent esophagoscopy relative to high-volume hospitals.
CONCLUSIONS: Patients with head and neck cancer who are undergoing diagnostic laryngoscopy are much more likely to undergo concurrent bronchoscopy and esophagoscopy at low- and medium-volume hospitals than at high-volume hospitals. Whether this represents overuse of concurrent procedures or appropriate care that leads to earlier diagnosis and better outcomes merits further investigation.
© 2013 American Cancer Society.

Entities:  

Keywords:  Michigan; Michigan State Ambulatory Surgery Databases; diagnostic techniques and procedures; endoscopy; head and neck cancer; hospital volume; otolaryngology

Mesh:

Year:  2013        PMID: 24114146      PMCID: PMC3867538          DOI: 10.1002/cncr.28379

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Primary care physician compliance with colorectal cancer screening guidelines.

Authors:  Jesse N Nodora; William D Martz; Erin L Ashbeck; Elizabeth T Jacobs; Patricia A Thompson; María Elena Martínez
Journal:  Cancer Causes Control       Date:  2011-06-28       Impact factor: 2.506

2.  Who receives their complex cancer surgery at low-volume hospitals?

Authors:  Waddah B Al-Refaie; Binyam Muluneh; Wei Zhong; Helen M Parsons; Todd M Tuttle; Selwyn M Vickers; Elizabeth B Habermann
Journal:  J Am Coll Surg       Date:  2011-11-23       Impact factor: 6.113

3.  Disparities in access to care at high-volume institutions for uro-oncologic procedures.

Authors:  Quoc-Dien Trinh; Maxine Sun; Jesse Sammon; Marco Bianchi; Shyam Sukumar; Khurshid R Ghani; Wooju Jeong; Ali Dabaja; Shahrokh F Shariat; Paul Perrotte; Piyush K Agarwal; Craig G Rogers; James O Peabody; Mani Menon; Pierre I Karakiewicz
Journal:  Cancer       Date:  2012-02-01       Impact factor: 6.860

4.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer.

Authors:  Paul L Nguyen; Xiangmei Gu; Stuart R Lipsitz; Toni K Choueiri; Wesley W Choi; Yin Lei; Karen E Hoffman; Jim C Hu
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

5.  Variation in lymph node examination after esophagectomy for cancer in the United States.

Authors:  Ryan P Merkow; Karl Y Bilimoria; Warren B Chow; Justin S Merkow; Michael J Weyant; Clifford Y Ko; David J Bentrem
Journal:  Arch Surg       Date:  2012-06

6.  Hospital inpatient costs for adults with multiple chronic conditions.

Authors:  Bernard Friedman; H Joanna Jiang; Anne Elixhauser; Andrew Segal
Journal:  Med Care Res Rev       Date:  2006-06       Impact factor: 3.929

7.  Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.

Authors:  Rosana S Rodrigues; Fernando A Bozza; Paul E Christian; John M Hoffman; Regan I Butterfield; Carl R Christensen; Marta Heilbrun; Richard H Wiggins; Jason P Hunt; Brandon G Bentz; Ying J Hitchcock; Kathryn A Morton
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

8.  Adequacy of lymph node examination in colorectal surgery: contribution of the hospital versus the surgeon.

Authors:  Kim F Rhoads; Leland K Ackerson; Justine V Ngo; Florette K Gray-Hazard; S V Subramanian; R Adams Dudley
Journal:  Med Care       Date:  2013-12       Impact factor: 2.983

9.  The cost of breast cancer screening in the Medicare population.

Authors:  Cary P Gross; Jessica B Long; Joseph S Ross; Maysa M Abu-Khalaf; Rong Wang; Brigid K Killelea; Heather T Gold; Anees B Chagpar; Xiaomei Ma
Journal:  JAMA Intern Med       Date:  2013-02-11       Impact factor: 21.873

10.  The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications.

Authors:  Kenneth B Roberts; Pamela R Soulos; Jeph Herrin; James B Yu; Jessica B Long; Edward Dostaler; Cary P Gross
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-20       Impact factor: 7.038

View more
  1 in total

1.  Prevalence and Outcomes of Head and Neck versus Non-Head and Neck Second Primary Malignancies in Head and Neck Squamous Cell Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database.

Authors:  Andrew C Birkeland; Andrew J Rosko; Steven B Chinn; Mark E Prince; Gordon H Sun; Matthew E Spector
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2016-02-25       Impact factor: 1.538

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.